Apixaban versus warfarin in patients with atrial fibrillation

Cited by (1,013)

Items 1,001–1,013 of 1,013

1. A rapid pro-hemostatic approach to overcome direct oral anticoagulants
   Thalji, Nabil K, Ivanciu, Lacramioara, Davidson, Robert, Gimotty, Phyllis A, Krishnaswamy, Sriram, Camire, Rodney M · 2016 · Nature Medicine
2. Timing of oral anticoagulant therapy in acute ischemic stroke with atrial fibrillation: study protocol for a registry-based randomised controlled trial
   Åsberg, Signild, Hijazi, Ziad, Norrving, Bo, Terént, Andreas, Öhagen, Patrik, Oldgren, Jonas · 2017 · Trials
3. Meta-analysis on risk of bleeding with apixaban in patients with renal impairment
   Pathak, Ranjan, Pandit, Anil, Karmacharya, Paras, Aryal, Madan Raj, Ghimire, Sushil, Poudel, Dilli Ram, Shamoun, Fadi E. · 2015 · The American Journal of Cardiology
4. Management of Patients With Atrial Fibrillation by Primary‐Care Physicians in Germany: 1‐Year Results of the <scp>ATRIUM</scp> Registry
   Kirchhof, Paulus, Schmalowsky, Janine, Pittrow, David, Rosin, Ludger, Kirch, Wilhelm, Wegscheider, Karl, Meinertz, Thomas, for the ATRIUM Study Group · 2014 · Clinical Cardiology
5. A Smartphone App to Improve Oral Anticoagulation Adherence in Patients With Atrial Fibrillation: Prospective Observational Study
   Senoo, Keitaro, Miki, Tomonori, Ohkura, Takashi, Iwakoshi, Hibiki, Nishimura, Tetsuro, Shiraishi, Hirokazu, Teramukai, Satoshi, Matoba, Satoaki · 2022 · JMIR mHealth and uHealth
6. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
   Roffi, Marco, Patrono, Carlo, Collet, Jean-Philippe, Mueller, Christian, Valgimigli, Marco, Andreotti, Felicita, Bax, Jeroen J., Borger, Michael A., Brotons, Carlos, Chew, Derek P. et al. · 2016 · European Heart Journal
7. Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus
   Fauchier, Laurent, Boriani, Giuseppe, de Groot, Joris R, Kreutz, Reinhold, Rossing, Peter, Camm, A John · 2021 · EP Europace
8. Anti-thrombotic therapy in patients with atrial fibrillation and intracranial hemorrhage
   Diener, Hans-Christoph, Stanford, Sophia, Abdul-Rahim, Azmil, Christensen, Louisa, Hougaard, Kristina Dupont, Bakhai, Ameet, Veltkamp, Roland, Worthmann, Hans · 2014 · Expert Review of Neurotherapeutics
9. Drug therapy in anticoagulation: which drug for which patient?
   Millar, Carolyn M, Laffan, Mike A · 2017 · Clinical Medicine
10. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
    Cosentino, Francesco, Grant, Peter J, Aboyans, Victor, Bailey, Clifford J, Ceriello, Antonio, Delgado, Victoria, Federici, Massimo, Filippatos, Gerasimos, Grobbee, Diederick E, Hansen, Tina Birgitte et al. · 2020 · European Heart Journal
11. Bleeding rates of veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism
    Howe, Zachary, Naville-Cook, Chad, Cole, Derek · 2019 · Journal of Thrombosis and Thrombolysis
12. Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events: 2026 ACC Scientific Statement
    Kumbhani, Dharam J., Armbruster, Anastasia L., Cheng, Richard K., Chrispin, Jonathan, Fischer, Urs, Holbrook, Anne Marie, Joglar, Jose, Sevestre, Marie-Antoinette · 2026 · JACC
13. Standard versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial
    Stewart, Simon, Ball, Jocasta, Horowitz, John D, Marwick, Thomas H, Mahadevan, Gnanadevan, Wong, Chiew, Abhayaratna, Walter P, Chan, Yih K, Esterman, Adrian, Thompson, David R et al. · 2015 · The Lancet